BLRX Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (25 Apr 2024 @ 16:00):

Stats
Today's Volume	636 119
Average Volume	418 608
Market Cap	53.19M
EPS	$0 ( 2024-03-26 )
Next earnings date	( $-0.290 ) 2024-05-22
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.640
ATR14	$0.00200 (0.35%)

Volume Correlation

Long: -0.14 (neutral)

Short: 0.12 (neutral)

Signal:(61.354) Neutral

BioLineRx Ltd. Correlation

10 Most Positive Correlations
HERA	0.975
AGGR	0.975
HERAU	0.974
GXII	0.974
CFIV	0.973
LGAC	0.973
RAM	0.973
AEAC	0.971
ACQR	0.97
AVAC	0.97

10 Most Negative Correlations
AEY	-0.978
WNEB	-0.975
EDUC	-0.975
MLKN	-0.972
AGIL	-0.969
SCKT	-0.968
PBHC	-0.968
BSBK	-0.963
OBT	-0.963
NURO	-0.962

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

BioLineRx Ltd. Correlation - Currency/Commodity

-0.41
( neutral )

-0.38
( neutral )

0.00
( neutral )

0.25
( neutral )

BioLineRx Ltd. Financials

Annual	2023
Revenue:	$4.80M
Gross Profit:	$174 000 (3.63 %)
EPS:	$-0.940

FY	2023
Revenue:	$4.80M
Gross Profit:	$174 000 (3.63 %)
EPS:	$-0.940

FY	2022
Revenue:	$0
Gross Profit:	$-654 000 (0.00 %)
EPS:	$-0.370

FY	2021
Revenue:	$0.00
Gross Profit:	$0.00 (0.00 %)
EPS:	$-0.600

Financial Reports:

No articles found.

BioLineRx Ltd.

BioLineRx Ltd., a clinical-stage biopharmaceutical development company, focuses on oncology. The company develops Motixafortide, a peptide, which has completed Phase 3 clinical trials for the treatment of autologous stem cell mobilization and Phase 2a clinical trials for the treatment of pancreatic cancer; and that is in Phase 2 clinical trials for the treatment of metastatic pancreatic adenocarcinoma patients, and Phase 1b clinical trials in patients with acute respiratory distress syndrome secondary to COVID-19 and other respiratory viral infections, as well as for the treatment of solid tumors and acute myeloid leukemia. It is also developing AGI-134, an immuno-oncology agent, which is in Phase 1/2a clinical trials for the treatment of solid tumors; and BL-5010, a customized, proprietary, pen-like applicator for the non-surgical removal of skin lesions. The company has collaboration agreement with MSD for the cancer immunotherapy field; MD Anderson Cancer Center to investigate the combination of Motixafortide with KEYTRUDA (pembrolizumab) in pancreatic cancer; and licensing arrangement with Perrigo Company plc for over-the-counter sale of BL-5010. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel.